
|Articles|March 25, 2020
Q2 Solutions Collaborates with University of Texas Medical Branch to Accelerate COVID-19 Vaccines
Advertisement
Q2 Solutions, a clinical trial laboratory services organization resulting from an IQVIA and Quest Diagnostics joint venture, announced its collaboration with the University of Texas Medical Branch to develop a novel assay for COVID-19 tests. Once a viable assay is developed, Q2 Solutions labs will produce it for use in clinical trials to determine the effectiveness of a COVID-19 vaccine.
For more information, click
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Honing the Power of AI for Next Generation Trial Oversight and Execution
2
A Look Back: AI and Pragmatic Trials Took Center Stage at SCOPE Summit 2025
3
ACT Brief: AI-Driven Oversight, Biotech Acceleration Strategies, and a Major Win in Bladder Cancer
4
Genentech’s Phase III MEERKAT and SANDCAT Trials Show Vision and Anatomical Gains With Vamikibart in Uveitic Macular Edema
5